Literature DB >> 21896300

Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: inverse association with positive symptoms.

Zhiwei Wu1, Xiang Yang Zhang, Huanhuan Wang, Wei Tang, Yu Xia, FeiXue Zhang, Jiahong Liu, Ye Fu, Jianjun Hu, Yuanling Chen, Linjing Liu, Da Chun Chen, Mei Hong Xiu, Thomas R Kosten, Jincai He.   

Abstract

Excessive free radical production or oxidative stress may be involved in the pathophysiology of schizophrenia as evidenced by increased superoxide dismutase (SOD) activities, a critical enzyme in the detoxification of superoxide radicals. This study compared plasma SOD activities in 78 never-medicated first-episode and 100 medicated chronic schizophrenia patients to 100 healthy control subjects and correlated these SOD activities with the Positive and Negative Syndrome Scale (PANSS) among the schizophrenic patients. We found that both first-episode and chronic patients had significantly increased plasma SOD activities compared to controls, and that chronic schizophrenic patients on antipsychotic medication had significantly higher SOD activities than first episode schizophrenic patients. Plasma SOD activities were also negatively correlated with positive symptoms of schizophrenia, but only in first-episode patients. Thus, oxidative stress appears to be greater in first episode schizophrenic patients with fewer positive symptoms and may become greater as schizophrenia becomes more chronic, although we cannot exclude the possibility that chronic antipsychotic treatment may increase SOD activities and presumed oxidative stress in schizophrenia.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21896300     DOI: 10.1016/j.pnpbp.2011.08.018

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  14 in total

1.  Sulforaphane Augments Glutathione and Influences Brain Metabolites in Human Subjects: A Clinical Pilot Study.

Authors:  Thomas W Sedlak; Leslie G Nucifora; Minori Koga; Lindsay S Shaffer; Cecilia Higgs; Teppei Tanaka; Anna M Wang; Jennifer M Coughlin; Peter B Barker; Jed W Fahey; Akira Sawa
Journal:  Mol Neuropsychiatry       Date:  2018-04-17

2.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

Review 3.  A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates.

Authors:  Sarel J Brand; Marisa Moller; Brian H Harvey
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

4.  Interrelationships Between BDNF, Superoxide Dismutase, and Cognitive Impairment in Drug-Naive First-Episode Patients With Schizophrenia.

Authors:  Mei Hong Xiu; Zezhi Li; Da Chun Chen; Song Chen; Maile E Curbo; Hanjing Emily Wu; Yong Sheng Tong; Shu Ping Tan; Xiang Yang Zhang
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

5.  Elevated plasma F2-isoprostane levels in schizophrenia.

Authors:  Ellen E Lee; Lisa T Eyler; Owen M Wolkowitz; Averria Sirkin Martin; Chase Reuter; Helena Kraemer; Dilip V Jeste
Journal:  Schizophr Res       Date:  2016-06-16       Impact factor: 4.939

Review 6.  Role of nitric oxide and related molecules in schizophrenia pathogenesis: biochemical, genetic and clinical aspects.

Authors:  Regina F Nasyrova; Dmitriy V Ivashchenko; Mikhail V Ivanov; Nikolay G Neznanov
Journal:  Front Physiol       Date:  2015-05-11       Impact factor: 4.566

7.  Diagnostic Accuracy of Brain-derived Neurotrophic Factor and Nitric Oxide in Patients with Schizophrenia: A pilot study.

Authors:  Vladimir V Djordjević; Dušan Lazarević; Vladan Ćosić; Marinela Z Knežević; Vidosava B Djordjević; Ivana Stojanović
Journal:  J Med Biochem       Date:  2015-12-30       Impact factor: 3.402

8.  Elevated activity of superoxide dismutase in male late-life schizophrenia and its correlation with clinical symptoms and cognitive deficits.

Authors:  Lijuan Huo; Xiaobing Lu; Fengchun Wu; Catherine Chang; Yuping Ning; Xiang Yang Zhang
Journal:  BMC Psychiatry       Date:  2021-12-04       Impact factor: 3.630

9.  Altered Antioxidant Defenses in Drug-Naive First Episode Patients with Schizophrenia Are Associated with Poor Treatment Response to Risperidone: 12-Week Results from a Prospective Longitudinal Study.

Authors:  Xi Rong Li; Mei Hong Xiu; Xiao Ni Guan; Yue Chan Wang; Jun Wang; Edison Leung; Xiang Yang Zhang
Journal:  Neurotherapeutics       Date:  2021-03-31       Impact factor: 7.620

Review 10.  Proteomic profiling in schizophrenia: enabling stratification for more effective treatment.

Authors:  Paul C Guest; Daniel Martins-de-Souza; Emanuel Schwarz; Hassan Rahmoune; Murtada Alsaif; Jakub Tomasik; Christoph W Turck; Sabine Bahn
Journal:  Genome Med       Date:  2013-03-26       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.